Edition:
United States

AmerisourceBergen Corp (ABC)

ABC on New York Consolidated

79.46USD
21 Nov 2017
Change (% chg)

$2.00 (+2.58%)
Prev Close
$77.46
Open
$77.83
Day's High
$79.57
Day's Low
$77.57
Volume
1,598,746
Avg. Vol
1,886,864
52-wk High
$97.85
52-wk Low
$71.90

Latest Key Developments (Source: Significant Developments)

AmerisourceBergen to acquire H. D. Smith
Monday, 20 Nov 2017 04:52pm EST 

Nov 20 (Reuters) - AmerisourceBergen Corp ::AmerisourceBergen to acquire H. D. Smith.AmerisourceBergen Corp - deal for ‍$815 million in cash​.AmerisourceBergen Corp - ‍plans to fund acquisition through issuance of new long-term debt​.AmerisourceBergen Corp - ‍acquisition is expected to be slightly accretive to adjusted diluted EPS in fiscal year 2018​.AmerisourceBergen Corp - ‍acquisition expected to achieve full run-rate synergies, be about $0.15 accretive to adjusted EPS in FY 2020​.AmerisourceBergen Corp - ‍company now expects fiscal year 2018 adjusted operating income growth to be in range of 4 percent to 7 percent​.AmerisourceBergen Corp - now sees revenue growth to be in range of 8 percent to 11 percent​ for fiscal year 2018.AmerisourceBergen Corp - ‍reaffirming rest of previously announced fiscal 2018 financial guidance​.AmerisourceBergen - expects fiscal year 2018 pharmaceutical distribution services segment operating income growth in range of 4 percent to 7 percent​.  Full Article

AmerisourceBergen increases dividend 4 percent
Thursday, 9 Nov 2017 09:00am EST 

Nov 9 (Reuters) - Amerisourcebergen Corp ::Increases dividend 4 percent.Increased company's quarterly dividend rate 4 percent to $0.38 per common share from $0.365 per common share​​.  Full Article

AmerisourceBergen, on conf call, says current trends indicate that generic buy side deflation rate has not worsened
Thursday, 2 Nov 2017 12:23pm EDT 

Nov 2 (Reuters) - AmerisourceBergen Corp ::AmerisourceBergen CEO, on conf call, says an aging U.S. patient population continues to "demand" the support of pharmaceutical intervention​.AmerisourceBergen CFO, on conf call - continue to experience headwind from lower Hepatitis C revenues this quarter, consistent with overall U.S. market trends.AmerisourceBergen CFO, on conf call - continue to see strong volume, revenue growth for oncology drugs due to expanded indications of overall market growth.AmerisourceBergen CFO, on conf call says our PharMEDium business experienced an increase in sequential shipping volumes in Q4.AmerisourceBergen CFO, on conf call, says current trends indicate that the generic buy side deflation rate has not worsened.AmerisourceBergen CFO, on conf call, says it is likely that only Q4 will have a full benefit of new pharmacies from Walgreens-Rite Aid deal.AmerisourceBergen CFO, on conf call, says transitioning customer contracts to more "balanced pricing" to offset lower contributions from generics.AmerisourceBergen, on conf call, when asked about Amazon's entry into drug supply chain, says "we haven't really counted Amazon at all yet as a threat".  Full Article

NY A.G. Schneiderman, coalition of AGs expand investigation into opioid crisis
Tuesday, 19 Sep 2017 12:39pm EDT 

Sept 19 (Reuters) - New York A.G. Schneiderman::New York A.G. Schneiderman, bipartisan coalition of AGs expand multistate investigation into opioid crisis.Says served subpoenas to Endo International, Janssen Pharmaceuticals, Teva Pharmaceutical/Cephalon Inc and Allergan.Says Attorneys General have also served a supplemental investigative subpoena on Purdue Pharma.Attorneys General demanded information about distribution practices from AmerisourceBergen, Cardinal Health, McKesson.  Full Article

AmerisourceBergen sets quarterly dividend of $0.365 per share
Thursday, 10 Aug 2017 09:29am EDT 

Aug 10 (Reuters) - AmerisourceBergen Corp ::Sets quarterly dividend of $0.365per share.  Full Article

Amerisourcebergen says have yet to see generic deflation ease from its current high single digits
Thursday, 3 Aug 2017 09:55am EDT 

Aug 3 (Reuters) - Amerisourcebergen Corp ::Says its distribution segment had revenue headwind of about 120 basis points due to lower Hepatitis C sales in the quarter.Says the 2016 june quarter was the last quarter we had instances of impactful generic drug price increases.Says to a lesser degree, we also had a headwind from lower brand inflation in the current quarter.Says for brand inflation, it's likey that inflation rate modelled for FY18 will be at low end or slightly below FY17 year range.Says have yet to see generic deflation ease from its current high single digits.Says at this point, expect the health care environment will be similar in fiscal'18 to this year.Says for 2017, one of the bigger impacts on revenues will just be in brand inflation.  Full Article

AmerisourceBergen sees FY 2017 adjusted earnings per share $5.82 to $5.92
Thursday, 3 Aug 2017 06:30am EDT 

Aug 3 (Reuters) - Amerisourcebergen Corp :Amerisourcebergen reports third quarter fiscal year 2017 results.Q3 adjusted earnings per share $1.43.Sees fy 2017 adjusted earnings per share $5.82 to $5.92.Q3 gaap earnings per share $0.23.Q3 revenue $38.7 billion versus i/b/e/s view $39.16 billion.Q3 earnings per share view $1.37 -- Thomson Reuters I/B/E/S.Sees 2017 non-gaap revenue growth in range of approximately 5 percent.Fy free cash flow to be approximately $750 million to $1 billion.Fy2017 earnings per share view $5.86, revenue view $155.10 billion -- Thomson Reuters I/B/E/S.Sees fy adjusted operating income to be approximately flat, compared to previous assumption of flat to up 2 percent.  Full Article

U.S. Senator Claire McCaskill opioid investigation expands to include distributors and additional manufacturers‍​
Thursday, 27 Jul 2017 08:30am EDT 

July 27 (Reuters) - Allergan Plc :U.S. Senator Claire McCaskill opioid investigation expands to include distributors and additional manufacturers‍​.U.S. Senator Claire McCaskill - newest requests for documents, information from opioid manufacturers were sent to Mallinckrodt, Endo, Teva, Allergan‍ ​.U.S. Senator Claire McCaskill - request to McKesson, AmerisourceBergen, Cardinal Health Inc focused on their distribution of opioid products.  Full Article

AmerisourceBergen says ‍announced a new organizational structure
Monday, 19 Jun 2017 06:30am EDT 

June 19 (Reuters) - Amerisourcebergen Corp :Says ‍announced a new organizational structure designed to further align organization to its customer needs​.Amerisourcebergen - customer-facing offerings to be aligned under 2 groups.Says co's operations will continue to be comprised of pharmaceutical distribution services reportable segment and other.Says ‍has also formed a new management committee to enable quicker, cross-functional decision-making​.  Full Article

Amerisourcebergen reports Q2 EPS $1.86
Thursday, 4 May 2017 06:30am EDT 

May 4 (Reuters) - Amerisourcebergen Corp :Amerisourcebergen reports second quarter fiscal year 2017 results.Adjusted diluted EPS guidance raised to $5.77 to $5.92 for fiscal year 2017.Q2 adjusted earnings per share $1.77.Continues to expect brand inflation of 7 pct to 9 pct and generic deflation of -7 pct to -9 pct for fiscal year 2017.Sees fy 2017 adjusted earnings per share $5.77 to $5.92.Q2 GAAP earnings per share $1.86.Q2 revenue $37.1 billion versus I/B/E/S view $38.09 billion.Q2 earnings per share view $1.68 -- Thomson Reuters I/B/E/S.Amerisourcebergen corp sees FY 2017 revenue growth in range of 5.5 percent to 6.5 percent, compared to previous assumption of 6.5 percent to 8 percent.Amerisourcebergen corp sees fiscal 2017 brand drug inflation in range of 7 percent to 9 percent.Amerisourcebergen corp sees fiscal 2017 generic drug deflation in range of -7 percent to -9 percent.Amerisourcebergen corp sees fiscal 2017 contributions from new generic launches similar to prior year.FY2017 earnings per share view $5.82, revenue view $156.48 billion -- Thomson Reuters I/B/E/S.  Full Article

AmerisourceBergen to pay $625 million to settle U.S. government probe

A unit of AmerisourceBergen Corp, one of the largest U.S. drug wholesalers, has agreed to pay $625 million to resolve a U.S. government probe involving pre-filled syringes, the company said in a filing with U.S. securities regulators on Tuesday.